Rajveer ‎‎’s Post

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

India's pharmaceutical industry continues to lead on the global stage, with pharmaceutical exports hitting USD 25 billion in FY 2023. India's role as a key supplier of generic drugs worldwide underscores its significance in providing affordable life-saving drugs to over 200 countries. The industry's compliance with international standards and contribution of over 60% to the global vaccine supply highlight its crucial impact, especially on developing nations. Despite these achievements, the heavy reliance on imported Active Pharmaceutical Ingredients (APIs) from China raises concerns. To address this, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to reduce API imports and promote domestic production. The Atmanirbhar Bharat initiative further emphasizes self-sufficiency by incentivizing API manufacturers to establish local production facilities. Looking forward, India aims to expand its pharmaceutical exports by venturing into new markets and enhancing focus on biotechnology and advanced research. By reducing dependency on imported raw materials and strengthening local API manufacturing, the industry is set to navigate through global disruptions towards a more resilient future.

The pharmaceutical sector, one of Bangladesh’s few knowledge- and technology-intensive industries, is anticipated to develop at a compound annual growth rate (CAGR) of more than 12% and reach a value of more than USD 6 billion between 2019 and 2025. Even during the pandemic in FY 2020, when other major sectors saw a decline in output, the pharmaceutical and medical chemicals business growth accelerated.

🌏 India's Crucial Role in the Global API Supply Chain 💊 Did you know that India supplies over 20% of the world’s Active Pharmaceutical Ingredients (APIs)? Known as the "Pharmacy of the World," India's pharmaceutical industry has been instrumental in providing affordable, high-quality APIs to leading markets like the U.S., Europe, Africa, and Latin America. Active Pharmaceutical Ingredients (APIs) are the biologically active components in medications that produce the intended therapeutic effects. APIs are the key ingredients in drugs responsible for the actual treatment or relief of the condition, while other ingredients, known as excipients, serve as delivery agents or fillers. APIs can be derived from chemical synthesis, natural sources, or biotechnology processes. As the world continues to depend on India for APIs, the focus on sustainability, innovation, and self-sufficiency will be crucial to meet future healthcare demands. #PharmacyOfTheWorld #APIsupplychain #HealthcareInnovation #MakeInIndia #Pharmaceuticals #Sustainability

In addition to reducing dependence and diversifying suppliers for semiconductors and critical minerals, the United States and Mexico have an opportunity to do the same for pharmaceuticals and active pharmaceutical ingredients. Jerry Haar and I look at some of the policy questions and challenges that should be addressed in order to capitalize on opportunities. https://lnkd.in/esr4z3kn #mexico #pharma #nearshoring

Generic drugs comprise over 90% of the U.S. market and 47% of those medications are imported from India. Senior Associate Andrew Rudman argues that India depends on China for almost two-thirds of its active pharmaceutical ingredients (APIs) required to produce those medications. Reliance on a single supplier for the vast majority of its critical inputs and components would be considered a serious risk. In a #new commentary, CSIS Americas Program Senior Associate Andrew I. Rudman analyzes the potential for closer cooperation between the United States and Mexico on strengthening pharmaceutical supply chains. Read the full analysis here: https://lnkd.in/eb5EHHjt

After successful trials, three local drug makers are gearing up for full-fledged commercial production of active pharmaceutical ingredients (APIs) at the BSCIC API Industrial Park in Munshiganj. ACME Laboratories, Ibn Sina Pharmaceutical, and Healthcare Pharmaceuticals are at the forefront of this industry advancement. The pharmaceutical sector in Bangladesh has made significant strides, transitioning from heavy import reliance to near self-sufficiency. The country now fulfills over 97% of its domestic pharmaceutical demand and exports medicines to 151 countries globally. Despite this progress, Bangladesh still imports around 85% of its required raw materials for API production, costing approximately $1.3 billion annually. The local industry produces APIs worth over Tk 2,000 crore yearly, but further investments from major companies are needed to meet local demand. While local production can currently only cover non-biological small molecule APIs, there is immense potential in this sector. With the domestic market worth approximately Tk 6,500 crore, expanding local API production remains a promising endeavor for the industry. #Pharmaceuticals #API #Bangladesh #IndustryTransformation #LocalProduction #HealthcareInvestment

Pharmaceuticals and biologics are among the most valuable and critical commodities shipped globally today. With drug manufacturers operating across borders, especially in key locations like Puerto Rico, Mexico, and Europe. North America and Europe lead in exporting temperature-sensitive pharmaceuticals by air. The World Health Organization predicts significant growth in the pharmaceutical industry in the coming years, with temperature-sensitive pharmaceuticals and biologics being the fastest-growing segment. Proper handling during transit and storage is crucial, as mishandling these sensitive products can render them ineffective or harmful. For shippers of temperature-controlled pharmaceuticals, it's essential to partner with freight forwarders and logistics providers with expertise in pharmaceutical cold chain management. Specialized packaging, including active and passive systems, ensures products remain within the required temperature ranges throughout the journey. Amerijet, certified by IATA’s CEIV Pharma program, guarantees that your pharmaceutical shipments are handled with the highest standards of safety, compliance, and care. With robust systems and procedures in place, Amerijet is committed to maintaining the integrity of the cold chain, delivering consistent quality and transparency every step of the way. #Amerijet #aircargo